Literature DB >> 8159778

PET studies of presynaptic monoamine metabolism in depressed patients and healthy volunteers.

H Agren1, L Reibring.   

Abstract

No deranged presynaptic monoamine metabolism in the brain has been directly demonstrated in mood disorders, in spite of the rich but indirect pharmacological evidence for a decreased efficacy of monoaminergic synaptic transmission in depression, especially as for serotonin. The availability of 11C-labelled 5-hydroxytryptophan (5-HTP) and L-DOPA, the direct precursors in the synthetic pathways to serotonin and dopamine, has allowed positron emission tomographic (PET) studies in 8 healthy volunteers and 6 patients suffering from unipolar depression. Main results indicate (1) decreased uptake of [11C]5-HTP and [11C]L-DOPA over the blood-brain barrier in depression (which is not altered by dietary tryptophan depletion in healthy volunteers), and (2) an increased utilization of [11C]5-HTP (but not [11C]L-DOPA), in the lower region of the medial prefrontal cortex, mainly of the left side. This phenomenon presumably mirrors an increased synthesis of serotonin in this area and might represent a local compensatory increase in a situation of a general serotonergic hypometabolism. Analyses of interactions of both ligands between striatal and prefrontal areas suggest significantly stronger positive correlations in depression than in health, that could be interpreted as a less pronounced autonomy between brain regions in depression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8159778     DOI: 10.1055/s-2007-1014265

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  16 in total

Review 1.  Reconsidering anhedonia in depression: lessons from translational neuroscience.

Authors:  Michael T Treadway; David H Zald
Journal:  Neurosci Biobehav Rev       Date:  2010-07-11       Impact factor: 8.989

2.  Positron emission tomography study of regional brain metabolic responses to a serotonergic challenge in major depressive disorder with and without comorbid lifetime alcohol dependence.

Authors:  Leo Sher; Matthew S Milak; Ramin V Parsey; Juan J Carballo; Thomas B Cooper; Kevin M Malone; Maria A Oquendo; J John Mann
Journal:  Eur Neuropsychopharmacol       Date:  2007-05-02       Impact factor: 4.600

Review 3.  Positron emission tomography molecular imaging in late-life depression.

Authors:  Kentaro Hirao; Gwenn S Smith
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-01-05       Impact factor: 2.680

4.  Imaging the pathophysiology of major depressive disorder - from localist models to circuit-based analysis.

Authors:  Michael T Treadway; Diego A Pizzagalli
Journal:  Biol Mood Anxiety Disord       Date:  2014-03-07

Review 5.  Measuring serotonin synthesis: from conventional methods to PET tracers and their (pre)clinical implications.

Authors:  Anniek K D Visser; Aren van Waarde; Antoon T M Willemsen; Fokko J Bosker; Paul G M Luiten; Johan A den Boer; Ido P Kema; Rudi A J O Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-27       Impact factor: 9.236

6.  Subgenual cingulate cortex volume in first-episode psychosis.

Authors:  Y Hirayasu; M E Shenton; D F Salisbury; J S Kwon; C G Wible; I A Fischer; D Yurgelun-Todd; C Zarate; R Kikinis; F A Jolesz; R W McCarley
Journal:  Am J Psychiatry       Date:  1999-07       Impact factor: 18.112

Review 7.  Functional neuroimaging in geriatric depression.

Authors:  Faith M Gunning; Gwenn S Smith
Journal:  Psychiatr Clin North Am       Date:  2011-04-08

Review 8.  Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners.

Authors:  G Huether; D Zhou; E Rüther
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

9.  DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder.

Authors:  Jonathan Savitz; Colin A Hodgkinson; Chantal Martin-Soelch; Pei-Hong Shen; Joanna Szczepanik; Allison C Nugent; Peter Herscovitch; Anthony A Grace; David Goldman; Wayne C Drevets
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-20       Impact factor: 5.176

10.  Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112.

Authors:  Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.